Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PD-1 Data Promise More Shake-ups In Melanoma Standard of Care

This article was originally published in The Pink Sheet Daily

Executive Summary

Studies presented at AACR highlight pros and cons of two new potential, competing frontline regimens in melanoma – Keytruda alone instead of Yervoy, or Yervoy in combination with Opdivo.

You may also be interested in...

Six Ways For PD-1 Lung Cancer Programs To Differentiate

The PD-1 and PD-L1 inhibitors have delivered stellar data in a number of tumor types and hold mega-blockbuster promise – but with so many in the class, sponsors are looking to stand out. Pull-out table provides side-by-side comparison of leading programs.

PD-1 Round-Up: Big Pharmas Talk Competitive Positioning

During first-quarter earnings calls, sponsors of PD-1/L1 immunotherapies defend their positions in the wake of new data and filings in April, and ahead of the annual ASCO meeting.

Amgen T-VEC’s Remaining Challenges: Getting To Market, Staying Relevant

After overwhelming but unenthusiastic endorsement from FDA’s advisory committee, the metastatic melanoma immunotherapy could still be hobbled by problematic trials as Amgen seeks approval path and prescriptions in rapidly changing disease space.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts